Cost-Effectiveness of Ranibizumab Versus Photodynamic Therapy for the Treatment of Neovascluar Age-Related Macular Degeneration Based in China Cost Setting
Nov 1, 2014, 00:00
10.1016/j.jval.2014.08.2128
https://www.valueinhealthjournal.com/article/S1098-3015(14)04058-3/fulltext
Title :
Cost-Effectiveness of Ranibizumab Versus Photodynamic Therapy for the Treatment of Neovascluar Age-Related Macular Degeneration Based in China Cost Setting
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(14)04058-3&doi=10.1016/j.jval.2014.08.2128
First page :
A609
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
1592